We claim:
1. A method of treating hot flashes in a mammal comprising administering to a mammal in need thereof an effective amount of duloxetine.
2. A method as claimed in claim 1 wherein the mammal is administered between 30 and 150 mg of duloxetine per day.
3. A method as claimed in claim 1 wherein the mammal is administered between 40 and 80 mg of duloxetine per day.
4. A method as claimed in claim 2 wherein the duloxetine is administered as an enteric capsule.
5. Duloxetine for use in the treatment of hot flashes.
6. A pharmaceutical formulation containing, as an active ingredient, duloxetine adapted for use in the treatment of hot flashes.
7. The use of duloxetine for the manufacture of a medicament for the treatment of hot flashes.
8. A method of treating hot flashes in a human undergoing raloxifene administration comprising administering an effective amount of duloxetine to a human in need thereof.
9. The method according to claim 7 where the raloxifene is raloxifene hydrochloride.
10. The method according to claim 7 where the administration of duloxetine and raloxifene is concurrent.
11. The method according to claim 9 where the administration of duloxetine and raloxifene is simultaneous.
12. The use of duloxetine for the manufacture of a medicament for treating hot flashes in a human female undergoing raloxifene administration.
13. A pharmaceutical formulation adopted for treatment of hot flashes in humans comprising duloxetine and raloxifene.
14. A method of treating hot flashes in a human undergoing estrogen replacement therapy comprising administering an effective amount of duloxetine to a human in need thereof.
15. The method according to claim 13 where the administration of duloxetine and estrogen replacement therapy are concurrent.
16. The method according to claim 14 where the administration of duloxetine and estrogen replacement therapy are simultaneous.
17. The use of duloxetine for the manufacture of a medicament for treatment of hot flashes in a human female undergoing estrogen replacement therapy.
18. A pharmaceutical formulation adopted for treatment of hot flashes in humans comprising duloxetine and estrogen replacement therapy.
19. A method of treating hot flashes in a human female comprising administering to a woman in need thereof an effective amount of duloxetine estrogen replacement therapy is contraindicated.
20. The use of duloxetine for the manufacture of a medicament for treatment hot flashes in a human female where estrogen replacement therapy is contraindicated.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A cable assembly comprising:
a cable connected to a terminal sub-assembly having, at a shifter end of the sub-assembly, a housing having a bore defining a laterally extending isolator socket;
a generally annular isolator disposed in the isolator socket, the isolator having a central bore having an inwardly extending annular flange defining a connector pin socket and a reverse clip cap socket at opposing sides of the flange within the central bore;
a reverse clip cap concentrically received by the reverse clip cap socket of the isolator, the reverse clip cap including a head portion and a generally cylindrical plug portion extending axially from the head portion to a free end and defining a connector pin end socket within the plug portion, the free end being inserted into the reverse clip cap socket of the isolator;
wherein the head portion of the reverse clip cap and the isolator are interlockably connected with one another when the plug portion is inserted into the reverse clip cap socket to prevent extraction of the reverse clip cap from the isolator; and
a connector pin comprising a shaft and a ball, the shaft extending through the connector pin socket of the isolator and the ball being received within the connector pin end socket of the reverse clip cap such that the connector pin, reverse clip cap and isolator are substantially coaxial with each other;
wherein the plug portion includes a deflectable wall that engages the connector pin shaft when the connector pin shaft is positioned in the connector pin socket of the isolator and the connector pin ball is received within the connector pin end socket of the reverse clip cap to prevent extraction of the connector pin from the reverse clip cap.
2. The cable assembly of claim 1, wherein the isolator engages both the reverse clip cap and the connector pin.
3. The cable assembly of claim 1, wherein the free end of the generally cylindrical plug portion has at least one relief slot formed in the deflectable wall.
4. The cable assembly of claim 1, wherein the head portion and the generally cylindrical plug portion are unitary.
5. The cable assembly of claim 1, wherein the connector pin end socket of the reverse clip cap is a ball socket.
6. The cable assembly of claim 5, wherein the ball socket of the reverse clip cap has at least one relief slot configured to enlarge the opening of the ball socket during engagement of the connector pin ball with the reverse clip cap.
7. The cable assembly of claim 1, wherein the reverse clip cap is formed of nylon 6-6.
8. The cable assembly of claim 1, wherein the generally annular isolator is received substantially concentrically by the isolator socket of the housing.
9. The cable assembly of claim 1, wherein the head portion of the reverse clip cap includes an annular flange extending radially beyond the plug portion, and wherein the flange of the reverse clip cap and the isolator have corresponding interlocking configurations that interlock with one another when the plug portion is inserted into the reverse clip cap socket.